COMMUNIQUÉS West-GlobeNewswire

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
27/08/2025
THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Back to School [...]
Alpha Tau to Participate in Five September Investor Conferences
27/08/2025
JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
27/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]
Commure Ambient AI Scores High Marks in KLAS First Look Report for Automating Provider Documentation & RCM
27/08/2025
KLAS research highlights Commure’s differentiated true ambient scribe technology, seamless integrations, and white-glove support model with forward-deployed engineers MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE [...]
Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria
27/08/2025
Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs BERKELEY, Calif, Aug. 27, [...]
Moleculin Issues New Positive AML Overall Survival Data:
27/08/2025
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8) Median OS of 2 nd Line efficacy evaluable population of 12 months (n=9) Median OS of Intent to Treat population (1L-7L) of 9 months (n [...]
Editas Medicine to Participate in Upcoming Investor Conferences
27/08/2025
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that [...]
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
27/08/2025
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the [...]
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
27/08/2025
Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care SAN DIEGO, Aug. 27, [...]
InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference
27/08/2025
MIAMI, Aug. 27, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright [...]
Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, delivering breakthrough image quality and FDA-cleared AI enhancements in cardiovascular ultrasound
27/08/2025
August 27, 2025 Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA [...]
MAPS Partners with Changemark to Advance Cannabis PTSD Research for Veterans
27/08/2025
MAPS takes critical step toward beginning formal site selection and recruitment for MJP2, a Phase 2 study of inhaled cannabis for PTSD in Veterans MAPS selects Changemark Research + Evaluation as Contract Research [...]
MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
27/08/2025
CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, [...]
BioNTX Announces BIO CEO John Crowley as Featured Speaker at iC³® Life Science & Healthcare Innovation Summit
27/08/2025
North Texas’ Premier Event Looks Toward “10 Years and Beyond” with Vision, Momentum, and an Innovation Renaissance DALLAS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- BioNTX , the leading biotechnology and healthcare innovation [...]
Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences
27/08/2025
BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation [...]
Mesoblast Financial Results and Corporate Update Webcast
27/08/2025
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and [...]
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
27/08/2025
BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for tolerability in the [...]
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
27/08/2025
Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025 SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on [...]
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
27/08/2025
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]

Pages